@article{malinowska_opportunities_2021,
 abstract = {Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may lead to coronavirus disease 2019 (COVID-19) which, in turn, may be associated with multiple organ dysfunction. In this review, we present advantages and disadvantages of cannabidiol (CBD), a non-intoxicating phytocannabinoid from the cannabis plant, as a potential agent for the treatment of COVID-19. CBD has been shown to downregulate proteins responsible for viral entry and to inhibit SARS-CoV-2 replication. Preclinical studies have demonstrated its effectiveness against diseases of the respiratory system as well as its cardioprotective, nephroprotective, hepatoprotective, neuroprotective and anti-convulsant properties, that is, effects that may be beneficial for COVID-19. Only the latter two properties have been demonstrated in clinical studies, which also revealed anxiolytic and antinociceptive effects of CBD (given alone or together with Î”9-tetrahydrocannabinol), which may be important for an adjuvant treatment to improve the quality of life in patients with COVID-19 and to limit post-traumatic stress symptoms. However, one should be aware of side effects of CBD (which are rarely serious), drug interactions (also extending to drugs acting against COVID-19) and the proper route of its administration (vaping may be dangerous). Clearly, further clinical studies are necessary to prove the suitability of CBD for the treatment of COVID-19.},
 author = {Malinowska, Barbara and Baranowska-Kuczko, Marta and Kicman, Aleksandra and Schlicker, Eberhard},
 copyright = {http://creativecommons.org/licenses/by/3.0/},
 doi = {10.3390/ijms22041986},
 file = {Snapshot:files/295/1986.html:text/html;Full Text PDF:files/296/Malinowska et al. - 2021 - Opportunities, Challenges and Pitfalls of Using Ca.pdf:application/pdf},
 journal = {International Journal of Molecular Sciences},
 keywords = {COVID-19, SARS-CoV-2, ACE2, cannabidiol, respiratory disease},
 language = {en},
 month = {January},
 note = {Number: 4
Publisher: Multidisciplinary Digital Publishing Institute},
 number = {4},
 pages = {1986},
 title = {Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19},
 url = {https://www.mdpi.com/1422-0067/22/4/1986},
 urldate = {2021-03-08},
 volume = {22},
 year = {2021}
}

